What Crinetics Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 18 |
| Total trades | 37 | 90 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 20,399 | 1,376,350 |
| Disposed | 1,905,000 | 3,038,580 |
| Net activity | −1,884,601 | −1,662,230 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wierenga Wendell | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Wierenga Wendell | Director | Sep 01 | Disposition to Issuer · D | −116,146 | $85.00 | −$9.87M | 5,925 |
| Nichols Weston | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Nichols Weston | Director | Sep 01 | Disposition to Issuer · D | −16,300 | $85.00 | −$1.39M | 5,925 |
| Vivaldi Coelho Rogerio | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Vivaldi Coelho Rogerio | Director | Sep 01 | Disposition to Issuer · D | −13,300 | $85.00 | −$1.13M | 5,925 |
| Okey Stephanie | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Okey Stephanie | Director | Sep 01 | Disposition to Issuer · D | −6,400 | $85.00 | −$544K | 5,925 |
| Deardorf Caren | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Deardorf Caren | Director | Sep 01 | Disposition to Issuer · D | −16,300 | $85.00 | −$1.39M | 5,925 |
| Bedrosian Camille L | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Bedrosian Camille L | Director | Sep 01 | Disposition to Issuer · D | −16,300 | $85.00 | −$1.39M | 5,925 |
| Fust Matthew K | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Fust Matthew K | Director | Sep 01 | Disposition to Issuer · D | −22,836 | $85.00 | −$1.94M | 5,925 |
| Kalofonos Isabel | Chief Commercial Officer | Sep 01 | Disposition to Issuer · D | −34,000 | $85.00 | −$2.89M | 0 |
| Kalofonos Isabel | Chief Commercial Officer | Sep 01 | Disposition to Issuer · D | −1,669 | $85.00 | −$142K | 34,000 |
| Betz Stephen F. | Chief Scientific Officer | Sep 01 | Disposition to Issuer · D | −79,650 | $85.00 | −$6.77M | 0 |
| Betz Stephen F. | Chief Scientific Officer | Sep 01 | Disposition to Issuer · D | −58,286 | $85.00 | −$4.95M | 79,650 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | Sep 01 | Disposition to Issuer · D | −71,471 | $85.00 | −$6.08M | 0 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | Sep 01 | Disposition to Issuer · D | −7,956 | $85.00 | −$676K | 71,471 |
Loading...